Education, Conference Coverage and Articles
Large language models, wearables and mobile health technologies are increasingly being explored across cardiovascular research and clinical care. At ESC Congress 2026, Dr Jazmin Aguado-Sierra discussed where these tools could add value, and where questions around reliability remain.
Dr Jazmin Aguado-Sierra discusses how computational models and digital twins are helping researchers understand different heart failure phenotypes, and how artificial intelligence can accelerate analysis and support more personalized approaches.
Phase IIb LUMINARA data presented at ESC Congress 2026 suggest that AZD5462 may improve cardiac remodeling and hemodynamics across different heart failure phenotypes, with the lowest dose producing the strongest remodeling signal in HFrEF.
Prof. Adriaan Voors discusses the evolving role of GLP-1 receptor agonists in heart failure, the importance of patient selection and monitoring, and how emerging evidence and new guidelines could influence clinical practice.
AMUNDSEN showed that immediate initiation of evolocumab after myocardial infarction substantially increased LDL-C goal achievement, but did not significantly reduce death or cardiovascular hospitalization at 1 year. Starting evolocumab immediately after myocardial infarction (MI) more than doubled the proportion of patients ...
The first dedicated ESC Guidelines on the management of cardiovascular disease and chronic kidney disease recommend kidney function and urine albumin testing in all patients with cardiovascular disease, with an emphasis on identifying CKD early and initiating effective treatment without delay.
New 2026 ESC Guidelines for the management of heart failure introduce major changes to the classification of heart failure and its treatment, with an increased focus on prevention, earlier intervention and timely referral of patients with advanced disease.
Direct oral anticoagulant (DOAC) therapy reduced adverse clinical events compared with no anticoagulation in patients with atrial fibrillation (AF) at intermediate risk of stroke, according to results from the SINGLE-AF trial presented during a Hot Line session at ESC Congress 2026.1
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.